News | Endeavour Vision

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth Geneva, February 20, 2020 - Endeavour Vision led the Series B funding round for Boston-based IntelyCare, along with Kaiser Permanente Ventures and Generator Ventures, allowing the company to [...]

Sarbjit Kunar2020-02-20T18:22:04+00:00February 20th, 2020|All News, Company News|

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage Endeavour Vision, Kaiser Permanente Ventures, and Generator Ventures Join Existing Investors in Round, Leveraging Gig Economics to Close Projected 1 Million Nurse Shortfall by 2030; Builds on Company’s Exceptional Momentum QUINCY, MA – February [...]

Sarbjit Kunar2020-02-20T14:06:24+00:00February 20th, 2020|All News, Company News|

Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that Tom Griffin has joined Nuvaira as Chief Financial Officer. Tom Griffin has a 30-year track record of strong leadership guiding [...]

Sarbjit Kunar2020-02-04T17:22:38+00:00February 4th, 2020|All News, Company News|

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinical stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug [...]

Sarbjit Kunar2020-01-06T14:14:02+00:00January 6th, 2020|All News, Company News|

Interview with Bradley Paddock, CEO of CeQur

Interview with Bradley Paddock, CEO of CeQur In June 2019, Bradley Paddock joined CeQur®, as Chief Executive Officer. We spoke to Bradley to hear about his first 6 months in the company and discuss the up-coming U.S. launch of its three-day insulin delivery device for type 2 diabetes. [...]

Sarbjit Kunar2020-01-06T11:51:06+00:00January 6th, 2020|All News, Blog|

Interview with Dennis Wahr, President and CEO, Nuvaira

Interview with Dennis Wahr, President and CEO, Nuvaira In 2019, Nuvaira was accepted into a unique program developed by the Haute Autorité de Santé (HAS, the French health technology assessment agency), the Forfait Innovation Program. We spoke to Nuvaira’s CEO Dennis Wahr to learn more. Can you summarise [...]

Sarbjit Kunar2020-01-06T13:59:57+00:00January 6th, 2020|All News, Blog|

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress 2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development [...]

fp_rick2019-11-29T16:01:15+00:00November 12th, 2019|All News, Company News|

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar [...]

Endeavour Vision2019-10-22T11:02:49+01:00October 14th, 2019|All News, Company News, Previous Sectors|

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension CAESAREA, Israel, September 12, 2019 – V-Wave Ltd., [...]

Endeavour Vision2019-10-10T10:05:26+01:00September 13th, 2019|All News, Company News|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy [...]

Endeavour Vision2019-10-10T10:53:56+01:00September 9th, 2019|All News, Company News, Previous Sectors|